Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments
Open accessThe DOI matches its Crossref record; 63 of the 66 references it cites were found in a registry or an index; 35 of the 66 sources its claims cite were checked for support.
Abstract
During weight loss, reductions in body mass are commonly described using molecular body components (eg, fat mass and fat-free mass [FFM]) or tissues and organs (eg, adipose tissue and skeletal muscle). While often conflated, distinctions between body components established by different levels of the 5-level model of body composition-which partitions body mass according to the atomic, molecular, cellular, tissue/organ, or whole-body level-are essential to recall when interpreting the composition of weight loss. A contemporary area of clinical and research interest that demonstrates the importance of these concepts is the discussion surrounding body composition changes with glucagon-like peptide-1 receptor agonists (GLP-1RA), particularly in regard to changes in FFM and skeletal muscle mass. The present article emphasizes the importance of fundamental principles when interpreting body composition changes experienced during weight loss, with a particular focus on GLP-1RA drug trials. The potential for obligatory loss of FFM due to reductions in adipose tissue mass and distribution of FFM loss from distinct body tissues are also discussed. Finally, selected countermeasures to combat loss of FFM and skeletal muscle, namely resistance exercise training and increased protein intake, are presented. Collectively, these considerations may allow for enhanced clarity when conceptualizing, discussing, and seeking to influence body composition changes experienced during weight loss.
Overview
CoChat Summary
## TL;DR
This article is a conceptual review arguing that body composition changes during GLP-1RA-associated weight loss need to be interpreted using fundamental body composition principles, especially the distinction between fat-free mass (FFM) and skeletal muscle mass. It also highlights resistance training and higher protein intake as plausible countermeasures to help preserve FFM and muscle during weight loss.
## Key findings
- The paper emphasizes that FFM and skeletal muscle are not interchangeable: FFM is a molecular-level construct, while skeletal muscle is an organ/tissue-level component, and the two can change differently during weight loss.
- Historical and contemporary weight-loss literature support a rough “quarter FFM” heuristic, but the proportion of weight lost as FFM varies by method and context; the paper reports median FFM losses of 14% for low-calorie diets and ~23% for very low-calorie diets, and 18% to 31% across specific surgical operations.
- The paper gives an example where, after a 9.5-kg loss of body mass, 1.5 kg was FFM loss; of that FFM loss, 0.9 kg (60%) was estimated to come from skeletal muscle, 0.1 kg (7%) from kidney/heart/liver, and 0.5 kg (33%) from adipose tissue fat-free component, GI tract, skin, or other sources.
- In a GLP-1RA-related example, adding exercise to liraglutide led to −4.7 kg FM with +0.5 kg FFM, whereas liraglutide alone led to −2.0 kg FM with 0.0 kg FFM; exercise alone produced +2.1 kg FFM with no statistically significant FM loss.
- The paper cites protein-intake studies suggesting benefits at higher intakes, including 1.6 g/kg during a 40% energy deficit, 1.1 to 1.6 g/kg outperforming 0.6 to 0.9 g/kg, and improved FFM retention with diets providing ≥25% of energy or >1.0 g/kg; it suggests 1.2 g/kg or greater or 20% or greater of total energy as a practical target.
## Methods
- This is a narrative/conceptual review focused on body composition principles relevant to interpreting GLP-1RA weight-loss trials, not an original empirical study.
- The authors state that they searched the historical and contemporary body composition literature for research establishing fundamental principles or illustrating body composition changes.
- The analysis is interpretive and comparative, using prior studies, theoretical corrections for obligatory FFM loss from adipose tissue, and examples from GLP-1RA, exercise, and protein-intake literature.
## Limitations
- The paper explicitly notes that direct comparisons within contemporary GLP-1RA trials are needed to establish whether FFM losses are similar across treatment types.
- It states there is currently a lack of research examining the effects of resistance training alongside GLP-1RA administration, so conclusions about that combination remain provisional.
- It also says there is limited research to inform differential protein requirements with GLP-1RA treatment, and that more work is warranted on nutrient intake and protein manipulation.
- Evident from the text: much of the discussion is conceptual and illustrative, relying on prior studies and theoretical adjustments rather than new data collected in this paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. The 5-level model of body composition. Adapted with permission from Wang et al [6]. Proportions are for illustrative purposes and are based on values from the Report of the Task Group on Reference Man [10]. Abbreviations: ECF, extracellular fluid; ECS, extracellular solids.](https://figures.cochat.ai/paper-figures/8801fdbfd48047b8bffbe2d55527fb2f/fundamental-body-composition-principles-provide-context-for-fat-free-and-figure-1.jpg)
![Figure 2. Interrelationships between molecular and organ/tissue levels of body composition assessment. Solid arrows indicate the molecules within anatomically defined organ/tissue components (ie, skeletal muscle and adipose tissue) contributing to molecular-level components (ie, fat-free mass and fat mass). “Fat” refers to nonpolar lipids, mainly triglycerides. In contrast, structural or polar lipids (eg, phospholipids, sphingomyelin), historically termed “essential fat,” are included within fat-free components. The dashed line indicates the small contribution of skeletal muscle triglyceride to fat mass. The small unlabeled portion at the top of the skeletal muscle mass stacked bar corresponds to the residual content of skeletal muscle (ie, fat, mineral, structural lipids, glycogen, and other small components). The bracketed portion of the adipose tissue mass stacked bar corresponds to the fat-free (lean) component of adipose tissue, containing water, protein, mineral, structural lipids, glycogen, and other small components. Data are for illustrative purposes and are based on values from the Report of the Task Group on Reference Man [10].](https://figures.cochat.ai/paper-figures/d2b1917529f543e7bb9a357ec272bcd8/fundamental-body-composition-principles-provide-context-for-fat-free-and-figure-2.jpg)
![Figure 3. Potential contributors to the proportion of weight lost as fat-free mass. Adapted with permission from Heymsfield et al [20]. ΔFFM/ΔW, change in fat-free mass relative to the change in weight.](https://figures.cochat.ai/paper-figures/01463f6c49ba439d89bd5b16fea5b355/fundamental-body-composition-principles-provide-context-for-fat-free-and-figure-3.jpg)
![Figure 4. Adjustment of fat-free mass changes for obligatory loss of the fat-free component of adipose tissue. The fat-free component of adipose tissue (FFAT) is approximated from fat mass changes reported by contemporary glucagon-like peptide-1 receptor agonist (GLP-1RA) trials as: FFAT≈Fatmass/0.85×0.15, when assuming that all fat mass loss is derived from adipose tissue and the fat content of adipose tissue is 85% [26, 27]. The fat-free component of adipose tissue is then subtracted from the reported fat-free mass changes, due to its obligatory nature, to provide an adjusted estimate of fat-free mass loss from non-adipose tissues. Data were obtained from published GLP-1RA trials [31-36].](https://figures.cochat.ai/paper-figures/34f49a5a4fd9448e847a2cc449ece313/fundamental-body-composition-principles-provide-context-for-fat-free-and-figure-4.jpg)
![Figure 5. Hypothetical distribution of fat-free mass and skeletal muscle loss during weight loss. Relationships between total fat-free mass loss and loss of fat-free mass from specific tissues and organs presented by Bosy-Westphal et al [29] are hypothetically applied to fat-free mass loss with glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reported by Wilding et al [34]. While the proportions between fat-free mass loss may vary between weight loss methods, the data are illustrative of the multiple tissue or organ sources contributing to fat-free mass loss.](https://figures.cochat.ai/paper-figures/5272d55ad519497295b6e50687ccc333/fundamental-body-composition-principles-provide-context-for-fat-free-and-figure-5.jpg)
Verification
Claims the paper makes
31 Valid · 0 Not valid · 20 Not checked · 7 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“a study directly comparing exercise modalities during a weight management program eliciting approximately 9% weight loss reported that the loss of thigh skeletal muscle volume was attenuated with resistance and concurrent training as compared to endurance training [28].”
§ Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments > Minimizing Loss of Fat-Free Mass and Skeletal Muscle Mass > Exercise Training Exercise of varying modalities may notably mitigate FFM loss during weight loss. One systematic review found the percentage of energy restriction interventions yielding 15% or more of weight loss as FFM was 81% for energy restriction alone, compared to only 39% for energy restriction plus exercise [37]. While the majority of exercise interventions in this analysis were endurance training, several included resistance training or concurrent (ie, endurance plus resistance) training. In addition to FFM preservation, research specifically examining skeletal muscle mass, as estimated by MRI or computed tomography, has also supported a protective effect both of endurance and resistance exercise during energy restriction [28, 38-40]. For example, Ross et al [38] evaluated MRI appendicular skeletal muscle mass changes in women with obesity who followed an energy-restricted diet (1000 kcal/d below weight-maintenance needs) alone or in combination with endurance exercise. After the 16-week treatment period, similar weight reduction of approximately 11% was experienced by both groups; however, loss of appendicular skeletal muscle was observed in the diet-only group, but not in the group who additionally performed endurance exercise. Additionally, the loss of whole-body lean volume, estimated by MRI, averaged 14% in the diet-only group, but was only 2% in the group performing exercise. In another investigation, the same researchers similarly observed preservation of MRI skeletal muscle and lean volume when a 1000 kcal/d energy deficit was implemented in conjunction with resistance exercise in women with obesity [39]. Furthermore, a study directly comparing exercise modalities during a weight management program eliciting approximately 9% weight loss reported that the loss of thigh skeletal muscle volume was attenuated with resistance and concurrent training as compared to endurance training [28]. Collectively, these results suggest that exercise training mitigates skeletal muscle loss during weight loss, and programs including resistance training may be particularly effective [41]. In the context of GLP-1RA treatment, Lundgren et al [23] demonstrated body composition benefits of participation in an exercise program in adults being treated with liraglutide. During an initial 8-week low-calorie diet completed by all participants, FM was reduced by 7.3 kg, on average, while FFM was reduced by 5.1 kg. Subsequently, participants were randomly assigned to liraglutide, exercise, liraglutide + exercise, or placebo for 1 year. The exercise program consisted of 2 weekly group exercise sessions (including interval-based cycling and circuit training) and 2 weekly individual sessions (primarily cycling, running, or brisk walking). Relative to the point of randomization, only the liraglutide + exercise group experienced statistically significant weight loss, produced by a decrease in FM (−4.7 kg) without change in FFM (+0.5 kg). In contrast, the liraglutide group significantly decreased FM (−2.0 kg) with no change in FFM (0.0 kg), while the exercise group experienced no statistically significant decrease in FM (−1.4 kg) but increased FFM (+2.1 kg). The placebo group increased both FM and FFM in similar quantities (+2.6 and +2.9 kg, respectively). In summary, the addition of exercise to liraglutide potentiated fat loss with FFM preservation, while exercise alone increased FFM without significant fat loss. Interestingly, a subsequent report including a 1-year posttreatment period following the initial trial concluded that the treatments including exercise led to superior maintenance of body weight and composition 1 year after termination of treatment as compared to liraglutide alone [22]. It was also reported that all groups had similar increases in FFM from initial randomization to the end of the 1-year posttreatment period (ie, weeks 0-104). Additional research including skeletal muscle estimation may aid the interpretation of these FFM findings, and GLP-1RA trials including exercise throughout the entire weight loss intervention are warranted. While many exercise modalities may offer health or body composition benefits [42], resistance training is considered the most effective nonpharmacological method of stimulating skeletal muscle growth or combatting muscle loss [43], with benefits observed not only for muscle mass, but also strength and physical function [44]. Although prolonged energy deficits employed during weight loss can attenuate resistance training-induced increases in FFM [45], resistance training can nonetheless mitigate losses of FFM during weight loss [28, 46]. Mechanistic research has demonstrated the ability of resistance training to prevent the typical reductions in both daily myofibrillar protein synthesis and postabsorptive muscle protein synthesis typically observed with energy restriction [47]. However, there is currently a lack of research examining the effects of resistance training alongside GLP-1RA administration, and this combined treatment approach should be investigated to determine if it enhances body composition changes, as well as supports superior body composition maintenance following treatment cessation. Interestingly, some preliminary work has supported possible benefits of GLP-1 and GLP-1RA for combatting muscle atrophy and myopathies related to inflammation. The putative effects—which include upregulation of myogenic factors, downregulation of atrophic factors, reductions in expression of inflammatory cytokines, mitochondrial preservation and biogenesis, and improvements in muscle microvasculature [48]—exhibit some overlap with responses to acute resistance exercise and adaptations to chronic resistance training [49-51]. Future work may clarify the relevance of these mechanisms in the context of combined GLP-1RA administration and resistance training. Appropriately designed resistance training is generally viewed as the most efficient method of increasing skeletal muscle mass and strength in adults [52-54] and therefore represents an appropriate modality to promote skeletal muscle preservation during weight loss. The Physical Activity Guidelines for Americans [55], endorsed by the Centers for Disease Control and Prevention and American College of Sports Medicine, includes, in addition to 150 minutes/week of moderate-intensity aerobic (endurance) activity, a recommendation to perform muscle-strengthening activities of moderate or greater intensity that activate all major muscle groups on 2 or more days each week. While these recommendations promote resistance training, they are generic and lack prescriptive detail regarding optimal program design. In that regard, a separate position statement by the American College of Sports Medicine provides recommendations for resistance training to promote muscle size and strength in healthy adults with limited or no prior resistance training experience [53]. Major components of these recommendations are summarized in Table 2. Forthcoming clinical trials should examine the potential of varying modalities and “doses” of exercise to help attenuate losses of FFM and skeletal muscle mass during GLP-1RA treatment.
What the sources say
- Supportedcites [28] Villareal, 2017, Aerobic or resistance exercise, or both, in dieting obese older adults, N Engl J Med source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable example is the use of appendicular lean soft tissue from dual-energy x-ray absorptiometry (DXA) to estimate skeletal muscle mass using magnetic resonance imaging (MRI)-based equations [16-18].”
§ Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments > The 5-Level Model In their seminal 1992 publication, Wang et al [6] defined the 5-level model of body composition to promote a more comprehensive and accurate system of body composition organization. This model allows for the categorization of total body mass according to 5 distinct levels: atomic, molecular, cellular, tissue/organ, and whole body (Fig. 1). Today, most accessible body composition assessment methods are based on the molecular level, which provides common metrics, such as body fat percentage, FM, and FFM. While familiar and useful, these metrics do not respect anatomy and simply represent the cumulative masses of different molecular components, wherever they occur in the body. In contrast, clinicians and researchers are often interested in understanding the quantities of anatomically defined components with physiological relevance, such as adipose tissue and skeletal muscle. As such, FM is often conflated with adipose tissue, and FFM is often conflated with skeletal muscle. However, these seemingly analogous pairs are in fact distinct in several regards. First, as stated, they belong to different levels of assessment according to the 5-level model, meaning that they are conceptually distinct. Related to this, the anatomical location of adipose tissue can be defined and investigated through imaging or dissection, while FM is distributed throughout the body, albeit with much of molecular fat typically occurring within adipose tissue. Despite this overlap, the complete molecular makeup of these paired entities differs (Fig. 2). FM is, by definition, entirely composed of fat molecules (ie, nonpolar lipids, mainly triglycerides), while adipose tissue is predominantly fat molecules (∼80%-85%), with additional contributions from water (∼15%) and protein (∼5%) [10]. When comparing the absolute quantity of FM and adipose tissue, values from reference data are similar (13.5 kg FM vs 15 kg adipose tissue in reference man; 16 kg FM vs 19 kg adipose tissue in reference woman [10]). While the approximately 80% to 85% of fat molecules from adipose tissue are also contained within FM, so are all other fat molecules distributed throughout the rest of the body. Many organs—including the liver and other splanchnic organs, skeletal muscle, bone, and others—contain small but variable quantities of nonpolar lipids [10]. Fat deposition in some of these locations is influenced by lifestyle and disease factors; in this regard, skeletal muscle and liver are noteworthy due to the association of increased fat deposition at these sites and adverse metabolic consequences, such as insulin resistance [11]. As with the previous comparison, the distinctions between FFM and skeletal muscle mass are noteworthy. It is frequently stated that FFM includes not only skeletal muscle but other components, such as organs, bone, and fluids. While well intentioned, such a statement intermeshes entities from multiple levels of assessment, namely the molecular (FFM) and organ/tissue (skeletal muscle, organs, bone). Molecularly, FFM consists of all nonfat molecules in the body, regardless of where they occur. The primary molecular categories within FFM include water (∼74%), protein (∼19%), mineral (∼6.5%), and a small residual component [10, 12]. While not discussed here, FFM may also be expected to include structural lipids (ie, polar lipids historically termed “essential fat” [13]). In contrast, skeletal muscle mass is the cumulative mass of the hundreds of anatomically defined skeletal muscles within the body. All major categories of molecules, including water, protein, minerals, glycogen, and lipids, are included within skeletal muscle tissue. While nearly all of skeletal muscle mass would be viewed as “lean” when considered at the molecular level (see Fig. 2), approximately 2% to 5% has been estimated to be lipid [10, 14], although the actual value likely varies based on the extent of intramuscular or intermuscular fat infiltration (eg, myosteatosis) [15]. Unlike the former comparison of FM and adipose tissue, the typical absolute quantities of FFM and skeletal muscle mass are notably disparate. Based on reference data, the quantity of FFM is more than double that of skeletal muscle mass (56.5 kg FFM vs 28 kg skeletal muscle mass for reference man; 42.0 kg FFM vs 17.0 kg skeletal muscle mass for reference woman [10]), although lifestyle practices such as exercise training could influence this relationship. In addition to the conceptual differences, the size disparity between FFM and skeletal muscle mass highlights the importance of avoiding a direct conflation of these entities. While molecular- and organ/tissue-level entities are conceptually distinct, the relationship between them can be leveraged to bridge from more accessible measurement techniques to outcomes of interest at another assessment level. A notable example is the use of appendicular lean soft tissue from dual-energy x-ray absorptiometry (DXA) to estimate skeletal muscle mass using magnetic resonance imaging (MRI)-based equations [16-18]. While lean soft tissue in the trunk region contains a substantial contribution from organs, the lean soft tissue estimates of the appendages are subject to much less confounding when establishing a relationship to skeletal muscle mass. That is, the proportion of molecular level lean soft tissue in the appendages that overlaps with skeletal muscle tissue is notably higher than for the trunk or total body [16]. As such, strong relationships between appendicular lean soft tissue and whole-body or segmental skeletal muscle have been leveraged to estimate an organ/tissue component from available molecular-level data [19].
What the sources say
- Supportedcites [16] McCarthy, 2023, Total and regional appendicular skeletal muscle mass prediction from dual-energy X-ray absorptiometry body composition models, Sci Rep source
The Introduction says DXA-measured appendicular lean mass was used as a predictor in skeletal-muscle-mass equations, with whole-body MRI as the reference measure. The Methods describe this paper’s own equations using DXA lean mass to predict MRI-measured skeletal muscle mass. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [17] Kim, 2004, Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults, J Appl Physiol source
- Not checked — no full text of the sourcecites [18] Kim, 2002, Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method, Am J Clin Nutr source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“many factors can influence individual changes in FFM relative to weight loss—including dietary intake, physical activity, aging, the metabolic and hormonal state—and individual factors like adiposity, race, and sex [20]”
§ Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments > Loss of Fat-Free Mass and Skeletal Muscle Mass During Weight Loss Historically, the “quarter FFM” rule stated that approximately 25% of weight can be expected to be lost as FFM. While there is some group-level support for this approximation, many factors can influence individual changes in FFM relative to weight loss—including dietary intake, physical activity, aging, the metabolic and hormonal state—and individual factors like adiposity, race, and sex [20] (Fig. 3). Given the current conversations about GLP-1RA treatments, the consideration of the method used to achieve weight loss is also noteworthy. A systematic review by Chaston et al [21] examined this question in the context of dietary, behavioral, pharmaceutical, and surgical interventions to produce substantial weight loss, albeit prior to widespread use of GLP-1RA. The median percentage of weight lost as FFM was 14% for low-calorie diets and approximately 23% for very low-calorie diets, regardless of whether exercise was included. Possible sex differences were also noted: When pooling estimates across dietary and behavioral weight loss interventions, the mean FFM loss was 27% for males and 20% for females. Limited evidence was available for pharmaceutical interventions (low-calorie diet plus sibutramine), with 2 included studies reporting FFM loss of more than 30% of weight loss. For surgical interventions, the median loss of FFM ranged from 18% to 31% across specific operations. While collectively supporting the “quarter FFM” rule as a general group-level approximation, direct comparisons within contemporary GLP-1RA trials are needed to establish the similarity of FFM losses across treatment types [22, 23]. As highlighted (see Fig. 2), adipose tissue has a fat-free or “lean” component that is composed primarily of water and protein and estimated to typically represent approximately 15% to 20% of adipose tissue mass [10]. When weight loss occurs, adipose tissue mass is typically reduced, leading to the loss of molecular level fat [24, 25] as well some degree of obligatory loss of the fat-free component of adipose tissue. When large magnitudes of weight loss occur, such as are common with the use of GLP-1RA drugs, the magnitude of obligatory FFM loss from adipose tissue may be sufficient to inappropriately influence the interpretation of total FFM loss, or the proportion of weight loss as FFM. However, the obligatory FFM loss from adipose tissue can be approximated mathematically [26, 27]. This adjustment leads to reductions in stated FFM loss in proportion with the magnitude of FM loss. For example, Abe et al [27] demonstrated how these corrections changed an apparent loss of FFM, relative to body mass lost, of 12% for weight loss in combination with resistance exercise to an increase of 4% [27, 28]. However, it is essential to note that such corrections assume that all FM loss is directly from adipose tissue. While this assumption is not entirely accurate [29, 30] and the previously described distinctions between molecular and organ/tissue components are important to recall, the assumption that the vast majority of FM loss occurs from adipose tissue is reasonable. As such, the theoretical calculations can be a useful heuristic for demonstrating obligatory loss from the fat-free component of adipose tissue. The same calculations can be applied to contemporary GLP1-RA weight loss trials, as demonstrated in Fig. 4. In addition to the consideration of the obligatory loss of FFM from adipose tissue, it is essential to recall that even corrected FFM is not directly synonymous with skeletal muscle mass. In many investigations, losses of FFM have been conflated with losses of skeletal muscle mass. However, research using MRI has demonstrated the varied tissue or organ sources of FFM loss during weight loss. Bosy-Westphal et al [29] found that in a group of women with overweight and obesity, a 9.5-kg loss of body mass resulted in a 1.5-kg loss of FFM during a low-energy diet. When examining the organ and tissue sources contributing to this molecular level loss of FFM, it was estimated that 0.9 kg (60% of FFM loss) originated from skeletal muscle, while 0.1 kg (7% of FFM loss) came from the kidney, heart, and liver; and 0.5 kg (33% of FFM loss) was due to the fat-free component of adipose tissue, the gastrointestinal tract, skin, or other unmeasured components. It is noteworthy that the estimation of the loss of FFM from adipose tissue would have been 1.4 kg using the previously discussed method (ie, 8.0kgFMloss0.85×0.15=1.4kg) [26, 27], while estimated change based on MRI quantification was smaller. Bosy-Westphal et al [29] further examined the skeletal muscle components being lost and estimated that, of the 0.9 kg of total skeletal muscle loss, 0.7 kg (46% of FFM loss) was due to reductions of water while only 0.15 kg (10% of FFM loss) was due to actual protein loss. While the proportions of different tissues lost may vary with distinct weight loss methods, the proportions reported by Bosy-Westphal et al [29] can be hypothetically applied to FFM loss reported in GLP-1RA trials for illustrative purposes (Fig. 5). While theoretical, these data nonetheless demonstrate that the entirety of FFM loss is not directly attributable to skeletal muscle and should not be interpreted as such. While the purpose of highlighting these considerations is not to minimize the importance of skeletal muscle for physiological function and well-being, they indicate that necessary context and nuance are warranted when interpreting FFM changes, particularly in the context of substantial weight loss.
What the sources say
- Partly supportedcites [20] Heymsfield, 2014, Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule, Obes Rev sourceExperimental — accuracy not yet measured
The With Diet, Growth and Aging, Metabolic-Hormonal State, and In Non-Obese Subjects sections support the roles of dietary restriction, exercise, aging, metabolic-hormonal state, adiposity, and sex in FFM changes relative to weight loss (pages unavailable). Race is less well supported: the Forbes Approach section considers race in an FFM prediction model but reports no race differences in its mid-range estimates of ΔFFM/ΔW. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“of the 0.9 kg of total skeletal muscle loss, 0.7 kg (46% of FFM loss) was due to reductions of water while only 0.15 kg (10% of FFM loss) was due to actual protein loss.”
§ Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments > Loss of Fat-Free Mass and Skeletal Muscle Mass During Weight Loss Historically, the “quarter FFM” rule stated that approximately 25% of weight can be expected to be lost as FFM. While there is some group-level support for this approximation, many factors can influence individual changes in FFM relative to weight loss—including dietary intake, physical activity, aging, the metabolic and hormonal state—and individual factors like adiposity, race, and sex [20] (Fig. 3). Given the current conversations about GLP-1RA treatments, the consideration of the method used to achieve weight loss is also noteworthy. A systematic review by Chaston et al [21] examined this question in the context of dietary, behavioral, pharmaceutical, and surgical interventions to produce substantial weight loss, albeit prior to widespread use of GLP-1RA. The median percentage of weight lost as FFM was 14% for low-calorie diets and approximately 23% for very low-calorie diets, regardless of whether exercise was included. Possible sex differences were also noted: When pooling estimates across dietary and behavioral weight loss interventions, the mean FFM loss was 27% for males and 20% for females. Limited evidence was available for pharmaceutical interventions (low-calorie diet plus sibutramine), with 2 included studies reporting FFM loss of more than 30% of weight loss. For surgical interventions, the median loss of FFM ranged from 18% to 31% across specific operations. While collectively supporting the “quarter FFM” rule as a general group-level approximation, direct comparisons within contemporary GLP-1RA trials are needed to establish the similarity of FFM losses across treatment types [22, 23]. As highlighted (see Fig. 2), adipose tissue has a fat-free or “lean” component that is composed primarily of water and protein and estimated to typically represent approximately 15% to 20% of adipose tissue mass [10]. When weight loss occurs, adipose tissue mass is typically reduced, leading to the loss of molecular level fat [24, 25] as well some degree of obligatory loss of the fat-free component of adipose tissue. When large magnitudes of weight loss occur, such as are common with the use of GLP-1RA drugs, the magnitude of obligatory FFM loss from adipose tissue may be sufficient to inappropriately influence the interpretation of total FFM loss, or the proportion of weight loss as FFM. However, the obligatory FFM loss from adipose tissue can be approximated mathematically [26, 27]. This adjustment leads to reductions in stated FFM loss in proportion with the magnitude of FM loss. For example, Abe et al [27] demonstrated how these corrections changed an apparent loss of FFM, relative to body mass lost, of 12% for weight loss in combination with resistance exercise to an increase of 4% [27, 28]. However, it is essential to note that such corrections assume that all FM loss is directly from adipose tissue. While this assumption is not entirely accurate [29, 30] and the previously described distinctions between molecular and organ/tissue components are important to recall, the assumption that the vast majority of FM loss occurs from adipose tissue is reasonable. As such, the theoretical calculations can be a useful heuristic for demonstrating obligatory loss from the fat-free component of adipose tissue. The same calculations can be applied to contemporary GLP1-RA weight loss trials, as demonstrated in Fig. 4. In addition to the consideration of the obligatory loss of FFM from adipose tissue, it is essential to recall that even corrected FFM is not directly synonymous with skeletal muscle mass. In many investigations, losses of FFM have been conflated with losses of skeletal muscle mass. However, research using MRI has demonstrated the varied tissue or organ sources of FFM loss during weight loss. Bosy-Westphal et al [29] found that in a group of women with overweight and obesity, a 9.5-kg loss of body mass resulted in a 1.5-kg loss of FFM during a low-energy diet. When examining the organ and tissue sources contributing to this molecular level loss of FFM, it was estimated that 0.9 kg (60% of FFM loss) originated from skeletal muscle, while 0.1 kg (7% of FFM loss) came from the kidney, heart, and liver; and 0.5 kg (33% of FFM loss) was due to the fat-free component of adipose tissue, the gastrointestinal tract, skin, or other unmeasured components. It is noteworthy that the estimation of the loss of FFM from adipose tissue would have been 1.4 kg using the previously discussed method (ie, 8.0kgFMloss0.85×0.15=1.4kg) [26, 27], while estimated change based on MRI quantification was smaller. Bosy-Westphal et al [29] further examined the skeletal muscle components being lost and estimated that, of the 0.9 kg of total skeletal muscle loss, 0.7 kg (46% of FFM loss) was due to reductions of water while only 0.15 kg (10% of FFM loss) was due to actual protein loss. While the proportions of different tissues lost may vary with distinct weight loss methods, the proportions reported by Bosy-Westphal et al [29] can be hypothetically applied to FFM loss reported in GLP-1RA trials for illustrative purposes (Fig. 5). While theoretical, these data nonetheless demonstrate that the entirety of FFM loss is not directly attributable to skeletal muscle and should not be interpreted as such. While the purpose of highlighting these considerations is not to minimize the importance of skeletal muscle for physiological function and well-being, they indicate that necessary context and nuance are warranted when interpreting FFM changes, particularly in the context of substantial weight loss.
What the sources say
- Partly supportedcites [29] Bosy-Westphal, 2009, Contribution of individual organ mass loss to weight loss-associated decline in resting energy expenditure, Am J Clin Nutr sourceExperimental — accuracy not yet measured
The Body composition section reports a mean loss of 923 g of skeletal muscle and 1.5 kg of fat-free mass, supporting the approximate 0.9 kg muscle-loss figure. It does not attribute 0.7 kg of that loss to water or 0.15 kg to protein, or report the claimed 46% and 10% breakdown. (LLM, conf=0.88)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Abe et al [27] demonstrated how these corrections changed an apparent loss of FFM, relative to body mass lost, of 12% for weight loss in combination with resistance exercise to an increase of 4% [27, 28].”
§ Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments > Loss of Fat-Free Mass and Skeletal Muscle Mass During Weight Loss Historically, the “quarter FFM” rule stated that approximately 25% of weight can be expected to be lost as FFM. While there is some group-level support for this approximation, many factors can influence individual changes in FFM relative to weight loss—including dietary intake, physical activity, aging, the metabolic and hormonal state—and individual factors like adiposity, race, and sex [20] (Fig. 3). Given the current conversations about GLP-1RA treatments, the consideration of the method used to achieve weight loss is also noteworthy. A systematic review by Chaston et al [21] examined this question in the context of dietary, behavioral, pharmaceutical, and surgical interventions to produce substantial weight loss, albeit prior to widespread use of GLP-1RA. The median percentage of weight lost as FFM was 14% for low-calorie diets and approximately 23% for very low-calorie diets, regardless of whether exercise was included. Possible sex differences were also noted: When pooling estimates across dietary and behavioral weight loss interventions, the mean FFM loss was 27% for males and 20% for females. Limited evidence was available for pharmaceutical interventions (low-calorie diet plus sibutramine), with 2 included studies reporting FFM loss of more than 30% of weight loss. For surgical interventions, the median loss of FFM ranged from 18% to 31% across specific operations. While collectively supporting the “quarter FFM” rule as a general group-level approximation, direct comparisons within contemporary GLP-1RA trials are needed to establish the similarity of FFM losses across treatment types [22, 23]. As highlighted (see Fig. 2), adipose tissue has a fat-free or “lean” component that is composed primarily of water and protein and estimated to typically represent approximately 15% to 20% of adipose tissue mass [10]. When weight loss occurs, adipose tissue mass is typically reduced, leading to the loss of molecular level fat [24, 25] as well some degree of obligatory loss of the fat-free component of adipose tissue. When large magnitudes of weight loss occur, such as are common with the use of GLP-1RA drugs, the magnitude of obligatory FFM loss from adipose tissue may be sufficient to inappropriately influence the interpretation of total FFM loss, or the proportion of weight loss as FFM. However, the obligatory FFM loss from adipose tissue can be approximated mathematically [26, 27]. This adjustment leads to reductions in stated FFM loss in proportion with the magnitude of FM loss. For example, Abe et al [27] demonstrated how these corrections changed an apparent loss of FFM, relative to body mass lost, of 12% for weight loss in combination with resistance exercise to an increase of 4% [27, 28]. However, it is essential to note that such corrections assume that all FM loss is directly from adipose tissue. While this assumption is not entirely accurate [29, 30] and the previously described distinctions between molecular and organ/tissue components are important to recall, the assumption that the vast majority of FM loss occurs from adipose tissue is reasonable. As such, the theoretical calculations can be a useful heuristic for demonstrating obligatory loss from the fat-free component of adipose tissue. The same calculations can be applied to contemporary GLP1-RA weight loss trials, as demonstrated in Fig. 4. In addition to the consideration of the obligatory loss of FFM from adipose tissue, it is essential to recall that even corrected FFM is not directly synonymous with skeletal muscle mass. In many investigations, losses of FFM have been conflated with losses of skeletal muscle mass. However, research using MRI has demonstrated the varied tissue or organ sources of FFM loss during weight loss. Bosy-Westphal et al [29] found that in a group of women with overweight and obesity, a 9.5-kg loss of body mass resulted in a 1.5-kg loss of FFM during a low-energy diet. When examining the organ and tissue sources contributing to this molecular level loss of FFM, it was estimated that 0.9 kg (60% of FFM loss) originated from skeletal muscle, while 0.1 kg (7% of FFM loss) came from the kidney, heart, and liver; and 0.5 kg (33% of FFM loss) was due to the fat-free component of adipose tissue, the gastrointestinal tract, skin, or other unmeasured components. It is noteworthy that the estimation of the loss of FFM from adipose tissue would have been 1.4 kg using the previously discussed method (ie, 8.0kgFMloss0.85×0.15=1.4kg) [26, 27], while estimated change based on MRI quantification was smaller. Bosy-Westphal et al [29] further examined the skeletal muscle components being lost and estimated that, of the 0.9 kg of total skeletal muscle loss, 0.7 kg (46% of FFM loss) was due to reductions of water while only 0.15 kg (10% of FFM loss) was due to actual protein loss. While the proportions of different tissues lost may vary with distinct weight loss methods, the proportions reported by Bosy-Westphal et al [29] can be hypothetically applied to FFM loss reported in GLP-1RA trials for illustrative purposes (Fig. 5). While theoretical, these data nonetheless demonstrate that the entirety of FFM loss is not directly attributable to skeletal muscle and should not be interpreted as such. While the purpose of highlighting these considerations is not to minimize the importance of skeletal muscle for physiological function and well-being, they indicate that necessary context and nuance are warranted when interpreting FFM changes, particularly in the context of substantial weight loss.
What the sources say
- Supportedcites [27] Abe, 2019, Body fat loss automatically reduces lean mass by changing the fat-free component of adipose tissue, Obesity (Silver Spring) source
Table 1 (page not available in our copy) reports that the diet-plus-resistance group lost 8.5 kg of body mass and 1.0 kg of uncorrected lean mass, while corrected lean mass increased by 0.3 kg. Relative to body mass lost, those changes are approximately 12% loss and 4% gain, respectively. (LLM, conf=0.94)
- Partly supportedcites [28] Villareal, 2017, Aerobic or resistance exercise, or both, in dieting obese older adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Results > Body Composition section (page unavailable) reports a 1.0 kg lean-mass loss alongside 8.5 kg body-weight loss in the resistance group—approximately 12% of the weight lost. It does not report corrections that turn this into a 4% increase, or attribute such a correction to Abe et al. (LLM, conf=0.87)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
33 more claims · 16 with their cited sources checked
Create a free account to see all 58 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In particular, adequate protein intake represents the cornerstone of nutritional prevention [40].”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“Among other factors, exercise and targeted nutritional intakes have been proposed to influence body composition outcomes during treatment with incretin-based medications, although these practices have been minimally examined in this context.7,12,13”
From Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series (2025) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“As resistance training is considered the most potent nonpharmacological stimulus for attenuating muscle loss and inducing skeletal muscle growth, it may be worthy of particular focus in these trials.7,22”
From Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series (2025) · cites this paper as [7]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Relationships between total fat-free mass loss and loss of fat-free mass from specific tissues and organs presented by Bosy-Westphal et al [29] are hypothetically applied to fat-free mass loss with glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reported by Wilding et al [34].”
MethodProgression Models in Resistance Training for Healthy Adults
(2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181915670 · Cited by 4,332
Report of the task group on reference man
(1979) · Annals of the ICRP · doi:10.1016/0146-6453(79)90123-4 · Cited by 1,706 · cited 7×
“2), adipose tissue has a fat-free or “lean” component that is composed primarily of water and protein and estimated to typically represent approximately 15% to 20% of adipose tissue mass [10].”
BackgroundMethodInfluentialObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506 · cited 1×
“While a shift in the focus of obesity treatment from weight management alone to improving patient-centered health outcomes has been promoted [3 ], weight loss remains a typical treatment goal.”
BackgroundPhysical Activity Guidelines for Americans
Bushman, B. A. (2019) · ACSMʼs Health & Fitness Journal · doi:10.1249/fit.0000000000000472 · Cited by 1,326
Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome — An allostatic perspective
Virtue, S., & Vidal-Puig, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.12.006 · Cited by 1,013 · cited 1×
“…influenced by lifestyle and disease factors; in this regard, skeletal muscle and liver are noteworthy due to the association of increased fat deposition at these sites and adverse metabolic consequences, such as insulin resistance [11]. a Historical definitions of lean body mass have been debated.”
BackgroundSkeletal muscle performance and ageing
Tieland, M., Trouwborst, I., & Clark, B. C. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12238 · Cited by 904 · cited 2×
“The reasoning provided for this goal is often the preservation of skeletal muscle mass due to its fundamental metabolic and functional importance [4, 5].”
BackgroundInternational Society of Sports Nutrition Position Stand: protein and exercise
Jäger, R., Kerksick, C. M., Campbell, B. I., Cribb, P. J., Wells, S. D., Skwiat, T. M., Purpura, M., Ziegenfuss, T. N., Ferrando, A. A., Arent, S. M., et al. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-017-0177-8 · Cited by 873 · cited 1×
“…intake include targeting 20 to 40 g of protein at each eating occasion, a quantity consistent with maximal stimulation of muscle protein synthesis [62]; consuming protein 3 or more separate times each day; and implementing behaviors that promote the target daily protein intake without the need…”
BackgroundLevesque, R. J. R. (2011) · Encyclopedia of Adolescence · doi:10.1007/978-1-4419-1695-2_447 · Cited by 853
Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults
Villareal, D. T., Aguirre, L., Gurney, A. B., Waters, D. L., Sinacore, D. R., Colombo, E., Armamento-Villareal, R., & Qualls, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616338 · Cited by 754
Cited by
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“3), increasing attention is now focused on body composition, muscle strength, functional activity and the proportion of loss of fat mass versus fat-free mass 164,165 .”
Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16275 · Cited by 181
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“Patients should be aware of these potential unwanted effects and, to minimize loss of muscle mass, encouraged to participate in resistance exercises and increase protein intake [179].”
Metadata
- Authors
- Tinsley, G. M., & Heymsfield, S. B.
- Affiliations
- Texas Tech University (US)
- Pennington Biomedical Research Center (US)
- Corresponding author
- Tinsley, Grant M
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2024-09-25
- Volume
- 8
- Issue
- 11
- Pages
- bvae164-bvae164
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC11450469
- OpenAlex
- W4402834318
- Semantic Scholar
- dd5329dcf5259225f6c3bd5c41609a86ac90e8d1
- Cited by
- 81
- References
- 66
- Citations by year
- 2026: 42 · 2025: 37 · 2024: 2
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the Endocrine Society (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Keywords
- body composition, fat-free mass, skeletal muscle mass, GLP-1 receptor agonists, weight loss, adipose tissue, resistance training, protein intake
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.